WebMay 16, 2024 · A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the Programmed Death Receptor-1 Blocking Antibody … WebJul 1, 2024 · Interventional (Clinical Trial) Actual Enrollment : 167 participants: Allocation: Randomized: Intervention Model: Parallel Assignment: Masking: Quadruple (Participant, …
Screening Hit to Clinical Candidate: Discovery of BMS …
WebPhase I - clinical trials investigating safety of an investigational medicine in a small number of human subjects. Phase II - clinical trials investigating dosing, safety and efficacy of an investigational medicine in a small … WebMay 3, 2024 · BMS-986378 (also known as CC-90010) belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block … saptco bus ticket price
CC-99677, a novel, oral, selective covalent MK2 inhibitor, …
WebJun 1, 2024 · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) announced positive results from the Phase 2 PAISLEY study evaluating deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, compared to placebo in patients with moderate to severe systemic lupus erythematosus (SLE). The study met the primary … WebApr 17, 2015 · A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies. Actual Study Start Date : June 19, 2015. Actual Primary Completion Date : WebJan 26, 2024 · Here, the safety, efficacy, and pharmacodynamics of ten BET inhibitors currently in clinical trials were evaluated. Methods: We retrieved and reviewed published reports on the clinical trials of twelve BET inhibitors including AZD5153, ABBV-075, BMS-986158, CPI-0610, GSK525762, OTX-015, PLX51107, INCB054329, INCB057643, FT … short to mid length hairstyles 2021